Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers

Advanced Drug Delivery Reviews

Volumn 60, Issue 4-5, 2008, Pages 548-558

  Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cell penetrating peptides; DNA; Intracellular delivery; Liposomes; Pharmaceutical nanocarriers; TAT peptide

Indexed keywords

DNA; DRUG DELIVERY; DRUG PRODUCTS; LIPOSOMES; PH EFFECTS;

CELL-PENETRATING PEPTIDES; DRUG-LOADED NANOCARRIERS; INTRACELLULAR DELIVERY; NANOPARTICULATE PHARMACEUTICAL CARRIERS;

PEPTIDES;

CELL PENETRATING PEPTIDE; DNA; LIPOSOME; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; POLYETHYLENEIMINE DERIVATIVE; TRANSACTIVATOR PROTEIN;

CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MICELLE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, TAT; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES;

EID: 38949192863     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.10.008     Document Type: Review

References (110)

1. Egleton R.D., and Davis T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18 (1997) 1431-1439
2. Park J.W., et al. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74 (2001) 95-113
3. Chakrabarti R., Wylie D.E., and Schuster S.M. Transfer of monoclonal antibodies into mammalian cells by electroporation. J. Biol. Chem. 264 (1989) 15494-15500
4. Arnheiter H., and Haller O. Antiviral sTATe against influenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins. EMBO J. 7 (1988) 1315-1320
5. Kamata H., Yagisawa H., Takahashi S., and Hirata H. Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. Nucleic Acids Res. 22 (1994) 536-537
6. Midoux P., et al. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug. Chem. 9 (1998) 260-267
7. Mastrobattista E., et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 277 (2002) 27135-27143
8. Lackey C.A., Press O.W., Hoffman A.S., and Stayton P.S. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug. Chem. 13 (2002) 996-1001
9. Roth J.A., et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 25 (1998) 33-37
10. Lisziewicz J., Sun D., Lisziewicz A., and Gallo R.C. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther. 2 (1995) 218-222
11. Farhood H., Serbina N., and Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1235 (1995) 289-295
12. Scheule R.K., et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8 (1997) 689-707
13. Filion M.C., and Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta 1329 (1997) 345-356
14. Tang F., and Hughes J.A. Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. Bioconjug. Chem. 10 (1999) 791-796
15. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science 287 (2000) 1969-1973
16. Venter J.C., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
17. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
18. Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr. Cancer Drug Targets 1 (2001) 33-47
19. Balmain A. Cancer genetics: from Boveri and Mendel to microarrays. Nat. Rev. Cancer 1 (2001) 77-82
20. Gibbs J.B., and Oliff A. Pharmaceutical research in molecular oncology. Cell 79 (1994) 193-198
21. Sawyer T.K. Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers 47 (1998) 243-261
22. Katz B.A. Structural and mechanistic determinants of affinity and specificity of ligands discovered or engineered by phage display. Ann. Rev. Biophys. Biomol. Struct. 26 (1997) 27-45
23. In: Cortese R. (Ed). Combinatorial Libraries: Synthesis, Screening and Application Potential (1995), Walter de Gruyter Berlin, New York
24. Hussain S.P., Hofseth L.J., and Harris C.C. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 34 Suppl 2 (2001) S7-S15
25. Lasic D.D. Liposomes: From Physics to Applications (1993), Elsevier, Amsterdam; New York
26. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
27. Allen T.M., et al. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 62 (1995) 199-204
28. In: Lasic D.D., and Martin F.J. (Eds). Stealth Liposomes (1995), CRC Press, Boca Raton
29. Torchilin V.P., Narula J., Halpern E., and Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1279 (1996) 75-83
30. Torchilin V.P., et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511 (2001) 397-411
31. Torchilin V.P., and Weissig V. Polymeric micelles for delivery of poorly soluble drugs. In: Park K., and Mrsny R.J. (Eds). Controlled drug delivery: designing technologies for the future (2000), American Chemical Society, Washington, D.C. 297-313
32. Maeda H., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
33. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 61 (2004) 2549-2559
34. Schwarze S.R., and Dowdy S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21 (2000) 45-48
35. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988) 1179-1188
36. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
37. Joliot A., Pernelle C., Deagostini-Bazin H., and Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. USA 88 (1991) 1864-1868
38. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88 (1997) 223-233
39. Pooga M., Hallbrink M., Zorko M., and Langel U. Cell penetration by transportan. FASEB J. 12 (1998) 67-77
40. Oehlke J., et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1414 (1998) 127-139
41. Rojas M., Donahue J.P., Tan Z., and Lin Y.Z. Genetic engineering of proteins with cell membrane permeability. Nat. Biotechnol. 16 (1998) 370-375
42. Futaki S., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001) 5836-5840
43. Lindgren M., Hallbrink M., Prochiantz A., and Langel U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21 (2000) 99-103
44. Zorko M., and Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57 (2005) 529-545
45. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
46. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
47. Elmquist A., Lindgren M., Bartfai T., and Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. 269 (2001) 237-244
48. Morris M.C., et al. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 (1997) 2730-2736
49. Jeang K.T., Xiao H., and Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription. Tat, J. Biol. Chem. 274 (1999) 28837-28840
50. Schwarze S.R., Hruska K.A., and Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 10 (2000) 290-295
51. Richard J.P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003) 585-590
52. Console S., et al. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278 (2003) 35109-35114
53. Lundberg M., Wikstrom S., and Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8 (2003) 143-150
54. Leifert J.A., Harkins S., and Whitton J.L. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9 (2002) 1422-1428
55. Vives E., Richard J.P., Rispal C., and Lebleu B. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 4 (2003) 125-132
56. Tyagi M., Rusnati M., Presta M., and Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001) 3254-3261
57. Sandgren S., Cheng F., and Belting M. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J. Biol. Chem. 277 (2002) 38877-38883
58. Mai J.C., et al. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277 (2002) 30208-30218
59. Violini S., et al. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry (Mosc.) 41 (2002) 12652-12661
60. Anderson R.G. The caveolae membrane system. Ann. Rev. Biochem. 67 (1998) 199-225
61. Fittipaldi A., et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278 (2003) 34141-34149
62. Rothbard J.B., et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126 (2004) 9506-9507
63. Kaplan I.M., Wadia J.S., and Dowdy S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 102 (2005) 247-253
64. Ferrari A., et al. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 8 (2003) 284-294
65. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
66. Potocky T.B., Menon A.K., and Gellman S.H. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J. Biol. Chem. 278 (2003) 50188-50194
67. Rothbard J.B., Jessop T.C., and Wender P.A. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Deliv. Rev. 57 (2005) 495-504
68. Pujals S., et al. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta 1758 (2006) 264-279
69. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 (2005) 637-651
70. Josephson L., Tung C.H., Moore A., and Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 10 (1999) 186-191
71. Lewin M., et al. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (2000) 410-414
72. Dodd C.H., et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 256 (2001) 89-105
73. Kaufman C.L., et al. Superparamagnetic iron oxide particles transactivator protein-fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging detection of cell migration: uptake and durability. Transplantation 76 (2003) 1043-1046
74. Tkachenko A.G., et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15 (2004) 482-490
75. Zhao M., Kircher M.F., Josephson L., and Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13 (2002) 840-844
76. Wunderbaldinger P., Josephson L., and Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug. Chem. 13 (2002) 264-268
77. Koch A.M., et al. Transport of surface-modified nanoparticles through cell monolayers. Chembiochem 6 (2005) 337-345
78. Pittet M.J., et al. Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat. Protoc. 1 (2006) 73-79
79. Cryan S.A., et al. Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation. Mol. Pharmacol. 3 (2006) 104-112
80. Liu J., Zhang Q., Remsen E.E., and Wooley K.L. Nanostructured materials designed for cell binding and transduction. Biomacromolecules 2 (2001) 362-368
81. Becker M.L., Remsen E.E., Pan D., and Wooley K.L. Peptide-derivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization. Bioconjug. Chem. 15 (2004) 699-709
82. Becker M.L., Bailey L.O., and Wooley K.L. Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjug. Chem. 15 (2004) 710-717
83. Santra S., et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem. Commun. (2005) 3144-3146 (Camb.)
84. Stroh M., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11 (2005) 678-682
85. de la Fuente J.M., and Berry C.C. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug. Chem. 16 (2005) 1176-1180
86. Mortensen M.W., et al. Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy. Bioconjug. Chem. 17 (2006) 284-290
87. Torchilin V.P., Rammohan R., Weissig V., and Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA 98 (2001) 8786-8791
88. Torchilin V.P., et al. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. USA 100 (2003) 1972-1977
89. Tseng Y.L., Liu J.J., and Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 62 (2002) 864-872
90. Marty C., et al. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci. 61 (2004) 1785-1794
91. Fretz M.M., et al. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim. Biophys. Acta 1665 (2004) 48-56
92. Yagi N., et al. Synthesis and evaluation of a novel lipid-peptide conjugate for functionalized liposome. Bioorg. Med. Chem. Lett. 17 (2007) 2590-2593
93. Sethuraman V.A., and Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 118 (2007) 216-224
94. Rudolph C., et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 21 (2004) 1662-1669
95. Suk J.S., et al. Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. Biomaterials 27 (2006) 5143-5150
96. Huang Z., Li W., MacKay J.A., and Szoka Jr. F.C. Thiocholesterol-based lipids for ordered assembly of bioresponsive gene carriers. Mol. Ther. 11 (2005) 409-417
97. Hyndman L., et al. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J. Control. Release 99 (2004) 435-444
98. Vandenbroucke R.E., De Smedt S.C., Demeester J., and Sanders N.N. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim. Biophys. Acta 1768 (2007) 571-579
99. Gupta B., Levchenko T., and Torchilin V.P. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol. Res. 16 (2007) 351-359
100. Kleemann E., et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J. Control. Release 109 (2005) 299-316
101. Juliano R.L. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. Ann. N. Y. Acad. Sci. 1082 (2006) 18-26
102. Zhang C., et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 112 (2006) 229-239
103. Palmer T.N., et al. The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta 797 (1984) 363-368
104. Jaracz S., Chen J., Kuznetsova L.V., and Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 13 (2005) 5043-5054
105. Gabizon A., Shmeeda H., Horowitz A.T., and Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56 (2004) 1177-1192
106. Widera A., Norouziyan F., and Shen W.C. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv. Drug Deliv. Rev. 55 (2003) 1439-1466
107. Lochmann D., Jauk E., and Zimmer A. Drug delivery of oligonucleotides by peptides. Eur. J. Pharm. Biopharm. 58 (2004) 237-251
108. Sawant R.M., et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17 (2006) 943-949
109. Kale A.A., and Torchilin V.P. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug. Chem. 18 (2007) 363-370
110. Kale A.A., and Torchilin V.P. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J. Drug Target. 15 (2007) 538-545